Menu

Clinical Evidence Lipogems

Lipogems® is a new and innovative treatment that has helped over 30,000 patients worldwide. It has been extensively researched, please see some of the key clinical papers below for more information. To see how the treatment could help you make an appointment our multidisciplinary team or call 0330 2233332 for more information.

Dr. Konrad Slynarski speaks to the Regenerative Clinic about his extensive experience using micro-fragmented adipose tissue stem cells in joint preservation and three year clinical studies in the field.

 

Vincenzo Condello incredible results show that the future of Orthobiologics has the potential to become a first-line treatment in sport medicine and joint preservation.

Clinical Papers Lipogems

Mesenchymal Stem Cells injection in hip osteoarthritis: preliminary results (Dall’Oca 2019) MSC Lipogems is a fairly easy technique. No adverse effects were recorded in our experience. Preliminary results showed a positive outcome according to all the grading systems used in this study even though a longer follow up is needed to validate this technique. Read full article.

Safety and Efficacy of Percutaneous Injection of Lipogems Micro-Fractured Adipose Tissue for Osteoarthritic Knee (Panchal 2018)
The injection of autologous, micro-fractured, minimally manipulated adipose tissue appears to be a safe and effective treatment option for patients with refractory, severe (grade 3 or 4) knee OA. This study demonstrated significant improvements in pain, quality of life, and function for at least 12 months in this study population. This intervention may represent a nonsurgical treatment option to avoid knee joint replacement in this population; however, further investigation is needed. Read full article.

Preliminary results of autologous adipose-derived stem cells in early knee osteoarthritis: identification of a subpopulation with greater response (Panni 2018)
The knee injection of adipose-derived stem cells associated to arthroscopic debridement increased significantly the clinical and functional scores in patients with early knee osteoarthritis at a mid-term follow-up, especially those with higher pre-operative visual analogue (VAS) scores. Read full article.

Autologous Fat Transfer for Thumb Carpometacarpal Joint Osteoarthritis: A Prospective Study (Herold 2017)
Autologous fat transplantation is an appealing alternative, especially in early-stage basal joint osteoarthritis of the thumb. The low invasiveness of the procedure and early recovery of patients compared with classical procedures such as trapeziectomy, and the superior long-term results compared with classical injection therapy, make this approach feasible as a first-line therapy in early-stage basal joint osteoarthritis of the thumb. Read full article.

Dr Morrison First Year Experience with Lipogems
First Year Experience with Lipogems

Allogeneic Mesenchymal Stem Cells and Recycled Autologous Chondrons Mixed in a One-Stage Cartilage Cell Transplantion (Windt 2017)
This first-in-man trial supports a paradigm shift in which mesenchymal stem cells are applied as augmentations or “signaling cells” rather than differentiating stem cells and opens doors for other applications. Read full article.

Arthroscopic treatment of chondral defects in the hip including microfragmented adipose tissue transplantation (Jannelli 2017)
Articular cartilage possesses only a weak capacity for repair; on the other hand, mesenchymal stem cells (MSCs) are specified as appropriate cell candidates for regenerating incurable defects of articular cartilage due to the following characteristics: inherent chondrogenic property, easy availability, cell homing potential and immunomodulatory function.

Besides bone marrow, multiple tissues have been reported to contain MSCs. These include adipose tissue, unlike bone marrow, adipose tissue derived MSCs can be isolated in large quantities with minimal morbidity and discomfort. Read full article. 

Mesenchymal Stem Cells and Regenerative Medicine: How Lipogems® Technology Make Them Easy, Safe and More Effective to Use (Tremolada 2017)
Lipogems® was designed to harvest, process and inject aspirated fat tissue which is washed, emulsified and rinsed, while adipose cluster dimensions are gradually reduced in a completely closed device by only mechanical forces. Lipogems® tissue product represents a natural implantable bioreactor that incorporates the main elements for a perfect natural regenerative response: the Scaffold (the adipose tissue structure), the Cells (Pericytes/MSCs), and the Grow factors (secreted cytokines and chemokines). Read full article.

The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteoglycan Synthesis in Patients with Knee Osteoarthritis (Hudetz 2017)
The results of our study indicate that the use of autologous and microfragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results. Read full article.

Autologous and micro-fragmented adipose tissue for the treatment of diffuse degenerative knee osteoarthritis (Russo 2017)
The results of this study show the safety and feasibility of using autologous and micro-fragmented adipose tissue in patients affected by diffuse degenerative chondral lesions. The technique is safe, minimally invasive, simple, one-step, with low percentage of complications, and compliant with the regulatory panorama. Read full article.

Mesenchymal Stem Cells Use In Hip Arthroscopy: Medium Term Results In Case-Control Study (Bajwa 2016)
Treatment of chondral defects with MSCs appears to offer safe and effective treatment and results are better sustained than the microfracture control group. Conversion to hip arthroplasty risk appears to decrease with MSC treatment in medium-term. Read full article.

Lipogems® Product Treatment Increases the Proliferation Rate of Human Tendon Stem Cells without Affecting Their Stemness and Differentiation Capability (Randelli 2016)
This study supports that directly activating human tendon stem cells with the Lipogems® lipoaspirate could represent a new practical therapeutic approach. In fact, obtaining a lipoaspirate is easier, safer, and more cost-effective than harvesting cells from tendon or bone marrow biopsies, expanding them in Good Manufacturing Practice facility and then re-injecting them in the patient. Read full article.

Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development (Tremolada Overview and Science 2016) Lipogems® technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes. Read full article.

Human Lipoaspirate as Autologous Injectable Active Scaffold for One-Step Repair of Cartilage Defects – In vitro (Bosetti 2015)
Research on mesenchymal stem cells from adipose tissue shows promising results for cell-based therapy in cartilage lesions. Read full article.

Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow (Zuk 2003)
Adipose tissue is an abundant and easily procured source of processes lipoaspirate cells, which have a potential like mesenchymal stem cells for use in tissue-engineering applications and as gene delivery vehicles. Read full article.